Be part of the knowledge - Global Oncology Academy

Medical News

Medical News
Research, Advocacy, Education Urged to Address Chronic Disease Through Food Is Medicine Programs
newsroom.heart.org
10/02/2023
Read more
Medical News
Cleveland Clinic Researchers Develop New Model for Prioritizing Lung Transplant Candidates
newsroom.clevelandclinic.org
10/02/2023
Read more
Medical News
Study Finds SARS-CoV-2-Associated Sepsis Was More Common, Deadly Than Previously Thought
medicalxpress.com
10/02/2023
Read more

See more news

Keeping Up With the Rapid Emergence of Strategies for Advanced Renal Cell Carcinoma
Keeping Up With the Rapid Emergence of Strategies for Advanced Renal Cell Carcinoma
CME/CE
Keeping Up With the Rapid Emergence of Strategies for Advanced Renal Cell Carcinoma
1.00 credit
- Mary Weinstein Dunn
  Peer
1.00 credit
Navigating NUT Carcinoma: Diagnosis and Treatment Strategies
Navigating NUT Carcinoma: Diagnosis and Treatment Strategies
Project Oncology®
Navigating NUT Carcinoma: Diagnosis and Treatment Strategies
- Jacob Sands, MD
  Peer
- Jia Luo, MD
  Peer
Choosing and Sequencing Regimens in Relapsed Multiple Myeloma
Choosing and Sequencing Regimens in Relapsed Multiple Myeloma
MinuteCE®
Choosing and Sequencing Regimens in Relapsed Multiple Myeloma
1.00 program credit
- Joseph Mikhael, MD
  Peer
1.00 program credit
Multiple Myeloma At First Relapse: Is My Patient Refractory to Lenalidomide?
Multiple Myeloma At First Relapse: Is My Patient Refractory to Lenalidomide?
MinuteCE®
Multiple Myeloma At First Relapse: Is My Patient Refractory to Lenalidomide?
1.00 program credit
- Noa Biran, MD
  Peer
1.00 program credit
Pomalidomide-Based Regimens in Early Relapse Multiple Myeloma
Pomalidomide-Based Regimens in Early Relapse Multiple Myeloma
MinuteCE®
Pomalidomide-Based Regimens in Early Relapse Multiple Myeloma
1.00 program credit
- Joseph Mikhael, MD
  Peer
1.00 program credit
Are There Other Novel Approaches or Targeted Therapies for Early Relapse?
Are There Other Novel Approaches or Targeted Therapies for Early Relapse?
MinuteCE®
Are There Other Novel Approaches or Targeted Therapies for Early Relapse?
1.00 program credit
- Noa Biran, MD
  Peer
1.00 program credit

CME/CE

Introducing Novel Agents Into the Armamentarium for Triple-Negative Breast Cancer
Introducing Novel Agents Into the Armamentarium for Triple-Negative Breast Cancer
CME/CE
Introducing Novel Agents Into the Armamentarium for Triple-Negative Breast Cancer
1.00 credit
- Terran Sims, MSN, ACNP-C, CNN, COCN-C
  Peer
- Laura M. Spring, MD
  Peer
1.00 credit
Keeping Up With the Rapid Emergence of Strategies for Advanced Renal Cell Carcinoma
Keeping Up With the Rapid Emergence of Strategies for Advanced Renal Cell Carcinoma
CME/CE
Keeping Up With the Rapid Emergence of Strategies for Advanced Renal Cell Carcinoma
1.00 credit
- Mary Weinstein Dunn
  Peer
1.00 credit
Choosing and Sequencing Regimens in Relapsed Multiple Myeloma
Choosing and Sequencing Regimens in Relapsed Multiple Myeloma
MinuteCE®
Choosing and Sequencing Regimens in Relapsed Multiple Myeloma
1.00 program credit
- Joseph Mikhael, MD
  Peer
1.00 program credit
Monoclonal Antibody-Based Regimens for Early Relapse Multiple Myeloma
Monoclonal Antibody-Based Regimens for Early Relapse Multiple Myeloma
MinuteCE®
Monoclonal Antibody-Based Regimens for Early Relapse Multiple Myeloma
1.00 program credit
- Noa Biran, MD
  Peer
1.00 program credit

Clinical Practice

Navigating NUT Carcinoma: Diagnosis and Treatment Strategies
Navigating NUT Carcinoma: Diagnosis and Treatment Strategies
Project Oncology®
Navigating NUT Carcinoma: Diagnosis and Treatment Strategies
- Jacob Sands, MD
  Peer
- Jia Luo, MD
  Peer
Multiple Myeloma At First Relapse: Is My Patient Refractory to Lenalidomide?
Multiple Myeloma At First Relapse: Is My Patient Refractory to Lenalidomide?
MinuteCE®
Multiple Myeloma At First Relapse: Is My Patient Refractory to Lenalidomide?
1.00 program credit
- Noa Biran, MD
  Peer
1.00 program credit
Pomalidomide-Based Regimens in Early Relapse Multiple Myeloma
Pomalidomide-Based Regimens in Early Relapse Multiple Myeloma
MinuteCE®
Pomalidomide-Based Regimens in Early Relapse Multiple Myeloma
1.00 program credit
- Joseph Mikhael, MD
  Peer
1.00 program credit
Are There Other Novel Approaches or Targeted Therapies for Early Relapse?
Are There Other Novel Approaches or Targeted Therapies for Early Relapse?
MinuteCE®
Are There Other Novel Approaches or Targeted Therapies for Early Relapse?
1.00 program credit
- Noa Biran, MD
  Peer
1.00 program credit

Programs

Biomarker Testing in NSCLC: Who, What, When?
Biomarker Testing in NSCLC: Who, What, When?
CME/CE
Biomarker Testing in NSCLC: Who, What, When?
1.00 credit
- Rasheda Persinger MSN, AGNP-C, AOCNP
  Peer
- Terran Sims, MSN, ACNP-C, CNN, COCN-C
  Peer
1.00 credit
Challenges in Myelodysplastic Syndromes (MDS): Risk Stratification and Integrating Novel Treatment Approaches
Challenges in Myelodysplastic Syndromes (MDS): Risk Stratification and Integrating Novel Treatment Approaches
CME/CE
Challenges in Myelodysplastic Syndromes (MDS): Risk Stratification and Integrating Novel Treatment Approaches
1.00 credit
- Sarah Tinsley-Vance, PhD, MSN, APRN-BC, AOCN
  Peer
- Terran Sims, MSN, ACNP-C, CNN, COCN-C
  Peer
1.00 credit
Case Study: How Do You Manage First Relapse Multiple Myeloma Following Daratumumab/Lenalidomide/Dexamethasone (DRd)?
Case Study: How Do You Manage First Relapse Multiple Myeloma Following Daratumumab/Lenalidomide/Dexamethasone (DRd)?
MinuteCE®
Case Study: How Do You Manage First Relapse Multiple Myeloma Following Daratumumab/Lenalidomide/Dexamethasone (DRd)?
1.00 program credit
- Noa Biran, MD
  Peer
- Joseph Mikhael, MD
  Peer
1.00 program credit
Is There a Role for Novel BCMA-Directed Cellular Therapies in Early Relapsed Multiple Myeloma?
Is There a Role for Novel BCMA-Directed Cellular Therapies in Early Relapsed Multiple Myeloma?
MinuteCE®
Is There a Role for Novel BCMA-Directed Cellular Therapies in Early Relapsed Multiple Myeloma?
1.00 program credit
- Joseph Mikhael, MD
  Peer
1.00 program credit